Acute endothelin-receptor inhibition does not attenuate acetylcholine- induced coronary vasoconstriction in experimental hypercholesterolemia

David Hasdai, Patricia Best, Charles R. Cannan, Verghese Mathew, Robert S. Schwartz, David Holmes, Amir Lerman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter (%ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced %ΔCAD at baseline and 10 weeks (-10 ± 2% and -12 ± 3%, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline (%ΔCAD -18 ± 8% for group I versus -12 ± 6% for group II; P=NS) but did at 10 weeks (%ΔCAD -77 ± 14% for group I versus -14 ± 6% for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline (%ΔCAD 5 ± 2% for group III versus 7 ± 3% for group IV, P=NS) or at 10 weeks (%ΔCAD -23 ± 12% for group III versus -19 ± 7% for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume18
Issue number1
StatePublished - 1998

Fingerprint

Endothelin Receptors
Hypercholesterolemia
Vasoconstriction
Acetylcholine
Endothelin-1
Vasoconstrictor Agents
Endothelins
Coronary Vessels
Swine
Cholesterol
Diet

Keywords

  • Acetylcholine
  • Endothelin
  • Endothelin receptor
  • Hypercholesterolemia
  • Pig

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Acute endothelin-receptor inhibition does not attenuate acetylcholine- induced coronary vasoconstriction in experimental hypercholesterolemia. / Hasdai, David; Best, Patricia; Cannan, Charles R.; Mathew, Verghese; Schwartz, Robert S.; Holmes, David; Lerman, Amir.

In: Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 18, No. 1, 1998, p. 108-113.

Research output: Contribution to journalArticle

@article{f0cb8b719dcd43e3b9c01e547ff907e9,
title = "Acute endothelin-receptor inhibition does not attenuate acetylcholine- induced coronary vasoconstriction in experimental hypercholesterolemia",
abstract = "Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter ({\%}ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced {\%}ΔCAD at baseline and 10 weeks (-10 ± 2{\%} and -12 ± 3{\%}, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline ({\%}ΔCAD -18 ± 8{\%} for group I versus -12 ± 6{\%} for group II; P=NS) but did at 10 weeks ({\%}ΔCAD -77 ± 14{\%} for group I versus -14 ± 6{\%} for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline ({\%}ΔCAD 5 ± 2{\%} for group III versus 7 ± 3{\%} for group IV, P=NS) or at 10 weeks ({\%}ΔCAD -23 ± 12{\%} for group III versus -19 ± 7{\%} for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.",
keywords = "Acetylcholine, Endothelin, Endothelin receptor, Hypercholesterolemia, Pig",
author = "David Hasdai and Patricia Best and Cannan, {Charles R.} and Verghese Mathew and Schwartz, {Robert S.} and David Holmes and Amir Lerman",
year = "1998",
language = "English (US)",
volume = "18",
pages = "108--113",
journal = "Arteriosclerosis, Thrombosis, and Vascular Biology",
issn = "1079-5642",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Acute endothelin-receptor inhibition does not attenuate acetylcholine- induced coronary vasoconstriction in experimental hypercholesterolemia

AU - Hasdai, David

AU - Best, Patricia

AU - Cannan, Charles R.

AU - Mathew, Verghese

AU - Schwartz, Robert S.

AU - Holmes, David

AU - Lerman, Amir

PY - 1998

Y1 - 1998

N2 - Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter (%ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced %ΔCAD at baseline and 10 weeks (-10 ± 2% and -12 ± 3%, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline (%ΔCAD -18 ± 8% for group I versus -12 ± 6% for group II; P=NS) but did at 10 weeks (%ΔCAD -77 ± 14% for group I versus -14 ± 6% for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline (%ΔCAD 5 ± 2% for group III versus 7 ± 3% for group IV, P=NS) or at 10 weeks (%ΔCAD -23 ± 12% for group III versus -19 ± 7% for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.

AB - Endothelin (ET) may mediate the enhanced coronary vasoconstriction associated with hypercholesterolemia. We hypothesized that short-term inhibition of ET receptors attenuates the coronary epicardial vasoconstrictor response to acetylcholine in experimental hypercholesterolemia. ET-1 (group I, n=5; 5 ng · kg-1 · min-1) and acetylcholine (group III, n=7; 10-6 to 10-4 mol/L) were given by intracoronary infusion in pigs. ET-1 and acetylcholine were also infused with the specific ETA-receptor blocker FR- 139317 (5 μg · kg-1 · min-1; group II, n=6; group IV, n=6). Acetylcholine was also infused with the combined ET-receptor blocker, bosentan (0.5 mg/kg plus 1 mg · kg-1 · h-1, group V, n=5). The ETB- receptor agonist sarafotoxin 6c (5 ng · kg-1 · min-1; n=4) was also infused. The percentage change in coronary artery diameter (%ΔCAD) to the infusions was measured at baseline and after 10 weeks of high-cholesterol diet in all animals. Sarafotoxin 6c mildly reduced %ΔCAD at baseline and 10 weeks (-10 ± 2% and -12 ± 3%, respectively). FR-139317 did not attenuate the epicardial vasoconstrictor response to ET-1 at baseline (%ΔCAD -18 ± 8% for group I versus -12 ± 6% for group II; P=NS) but did at 10 weeks (%ΔCAD -77 ± 14% for group I versus -14 ± 6% for group II; P<.05). FR-139317 did not affect the response to acetylcholine at baseline (%ΔCAD 5 ± 2% for group III versus 7 ± 3% for group IV, P=NS) or at 10 weeks (%ΔCAD -23 ± 12% for group III versus -19 ± 7% for group IV; P=NS). Bosentan did not affect the response to acetylcholine at baseline or 10 weeks. Short-term ET- receptor inhibition in experimental hypercholesterolemia attenuated the enhanced coronary epicardial vasoconstrictor effects of ET-1 but not acetylcholine-induced coronary epicardial vasoconstriction, suggesting that acetylcholine-induced coronary epicardial vasoconstriction may not be mediated by ET receptors.

KW - Acetylcholine

KW - Endothelin

KW - Endothelin receptor

KW - Hypercholesterolemia

KW - Pig

UR - http://www.scopus.com/inward/record.url?scp=0031984704&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031984704&partnerID=8YFLogxK

M3 - Article

C2 - 9445263

AN - SCOPUS:0031984704

VL - 18

SP - 108

EP - 113

JO - Arteriosclerosis, Thrombosis, and Vascular Biology

JF - Arteriosclerosis, Thrombosis, and Vascular Biology

SN - 1079-5642

IS - 1

ER -